IRENE GAVRAS, M. D.; LOUIS G. GRAFF, M.D.; BURTON D. ROSE, M.D.; JOHN M. McKENNA, M.D.; HANS R. BRUNNER, M.D.; HARALAMBOS GAVRAS, M.D.
Chronic inhibition of the angiotensin-converting enzyme has been used successfully in treating hypertension and congestive cardiac failure (1-4) over the past 3 years. The only oral angiotensin-converting enzyme inhibitor presently available for clinical use, captopril (Capoten, E. R. Squibb & Sons, Inc., Princeton, New Jersey), has been associated with a number of adverse reactions. These include skin rashes, sometimes preceded by fever, often accompanied by eosinophilia and lymphopenia; proteinuria, usually observed in patients with primary renal parenchymal disease; alteration or loss of taste; and recently, four cases of leukopenia with agranulocytosis (5-8). All these were transient and reversible by decreasing
Learn more about subscription options.
Register Now for a free account.
GAVRAS I, GRAFF LG, ROSE BD, McKENNA JM, BRUNNER HR, GAVRAS H. Fatal Pancytopenia Associated with the Use of Captopril. Ann Intern Med. 1981;94:58–59. doi: 10.7326/0003-4819-94-1-58
Download citation file:
Published: Ann Intern Med. 1981;94(1):58-59.
Cardiology, Coronary Risk Factors, Hematology/Oncology, HIV, Hypertension.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only